We have entered into an agreement with Novo Nordisk to acquire STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease.
Cellular Intelligence has secured global rights to Novo Nordisk’s Parkinson’s program, a clinical-stage allogeneic cell therapy for Parkinson's disease with FDA Fast Track Designation.
New white paper details key technical milestones and validation of the company’s proprietary, capsule-based platform to accelerate breakthroughs across human health.
Somite.ai, a company pioneering foundation models for human stem cells, today announced a strategic investment from AMD Ventures.
Somite builds foundation models for human stem cells. We’ve just raised over $47M in Series A funding led by Khosla Ventures to accelerate development of DeltaStem, our foundation model to produce any cell type for any person.